Identifying the optimal cutoff point for MGMT promoter methylation status in glioblastoma.

Q1 Medicine CNS Oncology Pub Date : 2021-09-01 Epub Date: 2021-09-06 DOI:10.2217/cns-2021-0002
Ngan Nguyen, Jordan Redfield, Matthew Ballo, Madison Michael, Jeffrey Sorenson, Daniel Dibaba, Jim Wan, Glenda Delgado Ramos, Manjari Pandey
{"title":"Identifying the optimal cutoff point for MGMT promoter methylation status in glioblastoma.","authors":"Ngan Nguyen,&nbsp;Jordan Redfield,&nbsp;Matthew Ballo,&nbsp;Madison Michael,&nbsp;Jeffrey Sorenson,&nbsp;Daniel Dibaba,&nbsp;Jim Wan,&nbsp;Glenda Delgado Ramos,&nbsp;Manjari Pandey","doi":"10.2217/cns-2021-0002","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> To define the optimal cutoff point for determining methylation status of O6-methylguanine-DNA methyltransferase (MGMT) by pyrosequencing in glioblastoma. <b>Patients & methods:</b> A retrospective study of 109 glioblastoma patients was performed to determine the optimal cutoff point for MGMT methylation status. <b>Results:</b> Receiver operating characteristic (ROC) analysis revealed 21% as the optimal cutoff (sensitivity: 68%; specificity: 59%) for MGMT methylation corresponding with the highest likelihood ratio of 1.66 and accuracy of 0.65. Methylation status (hazard ratio: 0.453; 95% CI: 0.279-0.735; p = 0.001) was associated with better overall survival. The crude model indicated linearity between methylation percent and survival rate; an increase of 10% of methylation resulted in a reduction of risk of death by 20% (p = 0.004). <b>Conclusion:</b> ROC analysis determined 21% as the optimal cutoff point for MGMT methylation status by pyrosequencing.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":"10 3","pages":"CNS74"},"PeriodicalIF":0.0000,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/14/0e/cns-10-74.PMC8461752.pdf","citationCount":"9","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/cns-2021-0002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/9/6 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 9

Abstract

Aim: To define the optimal cutoff point for determining methylation status of O6-methylguanine-DNA methyltransferase (MGMT) by pyrosequencing in glioblastoma. Patients & methods: A retrospective study of 109 glioblastoma patients was performed to determine the optimal cutoff point for MGMT methylation status. Results: Receiver operating characteristic (ROC) analysis revealed 21% as the optimal cutoff (sensitivity: 68%; specificity: 59%) for MGMT methylation corresponding with the highest likelihood ratio of 1.66 and accuracy of 0.65. Methylation status (hazard ratio: 0.453; 95% CI: 0.279-0.735; p = 0.001) was associated with better overall survival. The crude model indicated linearity between methylation percent and survival rate; an increase of 10% of methylation resulted in a reduction of risk of death by 20% (p = 0.004). Conclusion: ROC analysis determined 21% as the optimal cutoff point for MGMT methylation status by pyrosequencing.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
确定胶质母细胞瘤中MGMT启动子甲基化状态的最佳截止点。
目的:确定用焦磷酸测序法测定胶质母细胞瘤中o6 -甲基鸟嘌呤- dna甲基转移酶(MGMT)甲基化状态的最佳截止点。患者和方法:对109例胶质母细胞瘤患者进行回顾性研究,以确定MGMT甲基化状态的最佳截止点。结果:受试者工作特征(ROC)分析显示21%为最佳截止值(灵敏度:68%;特异性:59%)MGMT甲基化的最高似然比为1.66,准确率为0.65。甲基化状态(风险比:0.453;95% ci: 0.279-0.735;P = 0.001)与较好的总生存率相关。粗模型显示甲基化率与存活率呈线性关系;甲基化增加10%导致死亡风险降低20% (p = 0.004)。结论:ROC分析通过焦磷酸测序确定21%为MGMT甲基化状态的最佳截止点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CNS Oncology
CNS Oncology Medicine-Neurology (clinical)
CiteScore
3.80
自引率
0.00%
发文量
12
审稿时长
13 weeks
期刊最新文献
Novel insights toward diagnosis and treatment of glioneuronal and neuronal tumors in young adults. Autologous stem cell transplantation in adults with atypical teratoid rhabdoid tumor: a case report and review. Neurofilament light chain in serum of cancer patients with acute neurological complications. Development of brain metastases in non-small-cell lung cancer: high-risk features. The challenges and clinical landscape of glioblastoma immunotherapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1